SITE MAP
SARCLISA is now approved in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. MAT-US-2101240-v1.0-03/2021
Learn moreMAT-US-2101240-v1.0-03/2021
SITE MAP